Axonics (AXNX) Q3 2024 earnings summary

Executive summary

• Q3 2024 net revenue was $116.2M, up 25% year-over-year, driven by increased U.S. product sales and new account onboarding for sacral neuromodulation and Bulkamid.

• Gross margin improved to 77.2% from 74.2% in Q3 2023, reflecting higher sales volumes and favorable product mix.

• Operating expenses rose due to higher legal, personnel, marketing, R&D, and one-time litigation and merger-related fees.

• Net loss for Q3 2024 was $21,000, compared to net income of $3.9M in Q3 2023, impacted by $8M in one-time legal and acquisition-related costs.

• The pending merger with Boston Scientific remains under FTC review, with all closing conditions not yet satisfied.

Financial highlights

• Q3 2024 net revenue: $116.2M (+25% YoY); nine months: $322.2M (+25.5% YoY).

• Sacral neuromodulation revenue (Q3): $92.3M; Bulkamid revenue (Q3): $23.8M, both up 25% year-over-year.

• Gross profit for Q3: $89.7M; gross margin: 77.2% (vs. 74.2% prior year).

• Adjusted EBITDA: $23.6M vs. $14.0M prior year.

• Cash, cash equivalents, short-term investments, and restricted cash totaled $367M as of September 30, 2024.

Outlook and guidance

• Cash on hand expected to fund operations for at least the next 12 months.

• Revenue expected to fluctuate quarterly due to seasonality and market factors.

• Ongoing investments in sales, marketing, and R&D to support growth and product innovation.